Ramucirumab treatment in hepatocellular carcinoma

Federico Longo, Alfredo Carrato


Liver cancer is the sixth malignant tumor in incidence and the third in mortality worldwide with 781,631 deaths per year (1). Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Chronic liver disease and cirrhosis are present in most of the patients developing HCC.